Full Press Release Details
ASX, Nasdaq and Media Release
Opthea to Participate in the Leerink Partners Global Biopharma Conference
Melbourne, Australia, 06 March 2024, and Princeton, New Jersey, 05 March 2024 Opthea Limited (ASX:OPT; NASDAQ:OPT; Opthea ), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Authorized for release to ASX by Fred Guerard, CEO
| Investor Enquiries | Join our email database to receive program updates: |
| PJ Kelleher LifeSci Advisors Email: pkelleher@lifesciadvisors.com Media Silvana Guerci-Lena NorthStream Global Partners silvana@nsgpllc.com | Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com |